Free Trial

ImageneBio (IMA) Competitors

ImageneBio logo
$8.00 +0.61 (+8.25%)
As of 04:00 PM Eastern

IMA vs. VIRI, MGX, HURA, ZNTL, ABOS, ZYBT, IKT, SRZN, PLRX, and ARTV

Should you be buying ImageneBio stock or one of its competitors? The main competitors of ImageneBio include Virios Therapeutics (VIRI), Metagenomi (MGX), TuHURA Biosciences (HURA), Zentalis Pharmaceuticals (ZNTL), Acumen Pharmaceuticals (ABOS), Zhengye Biotechnology (ZYBT), Inhibikase Therapeutics (IKT), Surrozen (SRZN), Pliant Therapeutics (PLRX), and Artiva Biotherapeutics (ARTV). These companies are all part of the "pharmaceutical products" industry.

ImageneBio vs. Its Competitors

Virios Therapeutics (NASDAQ:VIRI) and ImageneBio (NASDAQ:IMA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, profitability, valuation and dividends.

Virios Therapeutics has a beta of 1.58, meaning that its stock price is 58% more volatile than the S&P 500. Comparatively, ImageneBio has a beta of 0.41, meaning that its stock price is 59% less volatile than the S&P 500.

ImageneBio's return on equity of -23.94% beat Virios Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Virios TherapeuticsN/A -130.33% -115.00%
ImageneBio N/A -23.94%-21.62%

9.1% of Virios Therapeutics shares are owned by institutional investors. Comparatively, 75.0% of ImageneBio shares are owned by institutional investors. 12.2% of Virios Therapeutics shares are owned by company insiders. Comparatively, 5.9% of ImageneBio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Virios Therapeutics has higher earnings, but lower revenue than ImageneBio. Virios Therapeutics is trading at a lower price-to-earnings ratio than ImageneBio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Virios TherapeuticsN/AN/A-$5.30M-$0.27-20.81
ImageneBio$9.16M3.50-$49.23M-$7.68-1.04

ImageneBio has a consensus target price of $33.67, suggesting a potential upside of 320.83%. Given ImageneBio's stronger consensus rating and higher probable upside, analysts plainly believe ImageneBio is more favorable than Virios Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Virios Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
ImageneBio
1 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.20

In the previous week, ImageneBio had 5 more articles in the media than Virios Therapeutics. MarketBeat recorded 5 mentions for ImageneBio and 0 mentions for Virios Therapeutics. Virios Therapeutics' average media sentiment score of 0.00 equaled ImageneBio'saverage media sentiment score.

Company Overall Sentiment
Virios Therapeutics Neutral
ImageneBio Neutral

Summary

ImageneBio beats Virios Therapeutics on 9 of the 13 factors compared between the two stocks.

Get ImageneBio News Delivered to You Automatically

Sign up to receive the latest news and ratings for IMA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IMA vs. The Competition

MetricImageneBioMED IndustryMedical SectorNASDAQ Exchange
Market Cap$29.60M$3.44B$6.23B$10.68B
Dividend YieldN/A2.26%5.71%4.82%
P/E Ratio-1.0423.9230.0629.84
Price / Sales3.50487.63587.23131.17
Price / CashN/A45.5737.0161.44
Price / Book0.2610.4012.046.60
Net Income-$49.23M-$52.62M$3.32B$276.82M
7 Day Performance6.10%2.08%1.79%2.07%
1 Month PerformanceN/A10.84%6.28%2.62%
1 Year Performance-61.01%13.57%61.13%32.86%

ImageneBio Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IMA
ImageneBio
2.9961 of 5 stars
$8.00
+8.3%
$33.67
+320.8%
-63.6%$29.60M$9.16M-1.0470News Coverage
Analyst Forecast
Gap Up
High Trading Volume
VIRI
Virios Therapeutics
N/A$6.19
+7.5%
N/A+34.5%$119.21MN/A-22.935
MGX
Metagenomi
3.1364 of 5 stars
$3.15
-5.9%
$10.00
+217.4%
+45.5%$118.97M$52.29M-1.34236
HURA
TuHURA Biosciences
1.1805 of 5 stars
$2.33
-5.1%
$12.67
+444.8%
N/A$118.81MN/A0.00N/AGap Down
ZNTL
Zentalis Pharmaceuticals
2.1737 of 5 stars
$1.65
+6.1%
$5.84
+255.0%
-50.6%$118.67M$67.43M-0.73160News Coverage
Positive News
Analyst Forecast
Gap Up
ABOS
Acumen Pharmaceuticals
3.0057 of 5 stars
$1.96
-7.8%
$7.00
+258.1%
-21.6%$118.42MN/A-0.8620
ZYBT
Zhengye Biotechnology
N/A$2.51
-4.9%
N/AN/A$118.39M$186.36M0.00278Gap Down
IKT
Inhibikase Therapeutics
0.0057 of 5 stars
$1.58
-2.5%
N/AN/A$117.74M$260K0.006News Coverage
SRZN
Surrozen
2.214 of 5 stars
$13.60
-1.4%
$38.50
+183.1%
+30.5%$116.55M$12.62M-0.9480Positive News
PLRX
Pliant Therapeutics
3.9923 of 5 stars
$1.88
+14.3%
$8.19
+336.7%
-87.7%$115.11M$1.58M-0.5590Options Volume
High Trading Volume
ARTV
Artiva Biotherapeutics
3.8871 of 5 stars
$4.72
-3.9%
$18.25
+286.7%
-55.8%$114.09M$250K0.0081Gap Up

Related Companies and Tools


This page (NASDAQ:IMA) was last updated on 10/24/2025 by MarketBeat.com Staff
From Our Partners